Personalizing cancer treatment
Close to 60% of cancer patients will receive radiotherapy as part of their treatment.
Up to 10% of patients treated by radiotherapy will develop irreversible side effects.
The identification of these patients before radiotherapy initiation is essential to adapt their care pathway.
Tests to predict tolerance to radiotherapy from a blood sample
Why to use a NovaGray test?
NovaGray tests assess the patient’s individual radiosensitivity. This is an important knowledge that can contribute to:
- reassure the patient before starting radiotherapy
- guide physicians in selecting the most appropriate treatment plan
- adapt the patient’s follow-up after radiotherapy
How to perform the test?
The test is performed before starting radiotherapy.
Our tests are recommended by the French Society of Radiation Oncology
The NovaGray technology has been validated in multi-center prospective clinical studies. The NovaGray tests are recommended by the French Society of Radiation Oncology (SFRO).